Phase I trial of AMV 602.
Latest Information Update: 16 Nov 2012
Price :
$35 *
At a glance
- Drugs AMV 602 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- 16 Nov 2012 Planned initiation date changed from 1 Dec 2012 to 1 Dec 2013.
- 16 Nov 2012 New trial record